HLA CLASS I BINDING T-CELL RECEPTOR TO MUTANT RAS
To provide a further therapy to cancer.SOLUTION: Provided is an isolated or purified T-cell receptor (TCR) that has antigen specificity to a mutant RAS amino acid sequence presented by a human leukocyte antigen (HLA) class I molecule. Also provided are associated polypeptide and protein, and associated nucleic acid, a recombinant expression vector, a host cell, a cell cluster, and a pharmaceutical composition. Also provided are a method for detecting the presence of cancer in a mammal, and a method for treating or preventing cancer in a mammal.SELECTED DRAWING: Figure 1A.
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 12. Dez. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
RAMI YOSEPH [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-12, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 |
---|
Patentnummer: |
JP2023175703 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA002963663 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA002963663 | ||
003 | DE-627 | ||
005 | 20240419122919.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240409s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA002963663 | ||
035 | |a (EPA)JP2023175703 | ||
035 | |a (EPA)64949411 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a RAMI YOSEPH |e verfasserin |4 aut | |
245 | 1 | 0 | |a HLA CLASS I BINDING T-CELL RECEPTOR TO MUTANT RAS |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-12, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 | ||
520 | |a To provide a further therapy to cancer.SOLUTION: Provided is an isolated or purified T-cell receptor (TCR) that has antigen specificity to a mutant RAS amino acid sequence presented by a human leukocyte antigen (HLA) class I molecule. Also provided are associated polypeptide and protein, and associated nucleic acid, a recombinant expression vector, a host cell, a cell cluster, and a pharmaceutical composition. Also provided are a method for detecting the presence of cancer in a mammal, and a method for treating or preventing cancer in a mammal.SELECTED DRAWING: Figure 1A | ||
650 | 4 | |a bio | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a LU YONG-CHEN |e verfasserin |4 aut | |
700 | 0 | |a GAL CAFRI |e verfasserin |4 aut | |
700 | 0 | |a ROSENBERG STEVEN A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 12. Dez. |
773 | 1 | 8 | |g year:2023 |g day:12 |g month:12 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/64949411/publication/JP2023175703A1?q=JP2023175703 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2023 |b 12 |c 12 |